GRFS vs HIMS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRFS presents a classic 'value trap' profile: strong deterministic health (Piotroski F-Score 7/9) and deep valuation discounts (Price < Graham Number < Intrinsic Value), yet it suffers from severe market rejection. While the stock trades at a significant discount to its Graham Number of $11.36 and Intrinsic Value of $18.88, this is offset by a 0/100 technical trend and a dismal earnings track record with 0 beats in the last 4 quarters. The disconnect between strong operational health scores and poor price performance suggests systemic risks or lack of catalyst for a reversal.
HIMS demonstrates strong operational health with a Piotroski F-Score of 7/9, signaling robust financial trends and efficiency. However, the stock is severely overvalued from a deterministic standpoint, trading at $29.39 against a Graham Number of $5.23 and an Intrinsic Value of $3.57. While revenue growth is strong (28.4%) and gross margins are impressive (73.83%), the valuation premium is extreme. This, combined with bearish insider selling and a negative technical trend, offsets the company's fundamental operational strengths.
Compare Another Pair
Related Comparisons
GRFS vs HIMS: Head-to-Head Comparison
This page compares Grifols, S.A. (GRFS) and Hims & Hers Health, Inc. (HIMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.